F Bonino

Summary

Affiliation: U.O. Gastroenterologia ed Epatologia
Country: Italy

Publications

  1. doi request reprint Liver stiffness, a non-invasive marker of liver disease: a core study group report
    Ferruccio Bonino
    Digestive and Liver Disease Unit, Department of Internal Medicine, University of Pisa, Pisa, Italy
    Antivir Ther 15:69-78. 2010
  2. ncbi request reprint Treatment of patients with chronic hepatitis C and cirrhosis
    F Bonino
    Gastroenterologia and Epatologia, Spedali Riuniti di Santa Chiara, Azienda Ospedaliera Pisana, Cisanello, Pisa, Italy
    J Hepatol 31:197-200. 1999
  3. ncbi request reprint Hepatitis C virus infection: early diagnosis and identification of response to antiviral therapy
    F Bonino
    Azienda Ospedaliera Universitaria Pisana, Via Paradisa 2, 56124 Cisanello Pisa, Italy
    Expert Rev Mol Diagn 1:310-4. 2001
  4. ncbi request reprint Colorectal cancer. A novel approach to adjuvant chemotherapy with fluoropyrimidines
    F Bonino
    Ospedale Maggiore, Policlinico, IRCCS, Milan, Italy
    Dig Liver Dis 34:396-7. 2002
  5. doi request reprint Diagnostic markers of chronic hepatitis B infection and disease
    Ferruccio Bonino
    Digestive and Liver Disease Unit, Department of Internal Medicine, University of Pisa, Pisa, Italy
    Antivir Ther 15:35-44. 2010
  6. pmc Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B
    F Bonino
    University of Pisa and Foundation IRCCS, Policlinico di Milano, Milan, Italy
    Gut 56:699-705. 2007
  7. ncbi request reprint Chronic hepatitis B e antigen (HBeAg) negative, anti-HBe positive hepatitis B: an overview
    Ferruccio Bonino
    Direzione Scientifica, Ospedale Maggiore di Milano, Policlinico, IRCCS, Via Francesco Sforza, 28, 20122 Milan, Italy
    J Hepatol 39:S160-3. 2003
  8. doi request reprint Early and accurate prediction of Peg-IFNs/ribavirin therapy outcome in the individual patient with chronic hepatitis C by modeling the dynamics of the infected cells
    P Colombatto
    UO Epatologia SSN, Azienda Ospedaliero Universitaria Pisana, Pisa, Italy
    Clin Pharmacol Ther 84:212-5. 2008
  9. ncbi request reprint Emergence of hepatitis B virus quasispecies with lower susceptibility to nucleos(t)ide analogues during lamivudine treatment
    F Moriconi
    UO Gastroenterologia ed Epatologia Ospedaliera, University Hospital of Pisa, Pisa, Italy
    J Antimicrob Chemother 60:341-9. 2007
  10. ncbi request reprint Impact of antiviral treatment on recurrence of hepatitis B virus infection and disease
    P Ciccorossi
    U O Gastroenterologia e Epatologia, Azienda Ospedaliera Pisana e Università di Pisa, Pisa, Italy
    Transplant Proc 35:1028-9. 2003

Collaborators

Detail Information

Publications31

  1. doi request reprint Liver stiffness, a non-invasive marker of liver disease: a core study group report
    Ferruccio Bonino
    Digestive and Liver Disease Unit, Department of Internal Medicine, University of Pisa, Pisa, Italy
    Antivir Ther 15:69-78. 2010
    ..The group concluded that FibroScan(®) is a valuable, non-invasive technique and have developed a consensus report form for registering transient elastography results. In this article, we report the findings of the study group...
  2. ncbi request reprint Treatment of patients with chronic hepatitis C and cirrhosis
    F Bonino
    Gastroenterologia and Epatologia, Spedali Riuniti di Santa Chiara, Azienda Ospedaliera Pisana, Cisanello, Pisa, Italy
    J Hepatol 31:197-200. 1999
    ..Prospective, randomized clinical trials should be performed after stratification of these patients for stage and cofactors of liver disease...
  3. ncbi request reprint Hepatitis C virus infection: early diagnosis and identification of response to antiviral therapy
    F Bonino
    Azienda Ospedaliera Universitaria Pisana, Via Paradisa 2, 56124 Cisanello Pisa, Italy
    Expert Rev Mol Diagn 1:310-4. 2001
    ..Some of the current issues and perspectives involved in detection and quantification of viral load during the incubation phase of infection and monitoring the early phase of antiviral therapy are discussed...
  4. ncbi request reprint Colorectal cancer. A novel approach to adjuvant chemotherapy with fluoropyrimidines
    F Bonino
    Ospedale Maggiore, Policlinico, IRCCS, Milan, Italy
    Dig Liver Dis 34:396-7. 2002
  5. doi request reprint Diagnostic markers of chronic hepatitis B infection and disease
    Ferruccio Bonino
    Digestive and Liver Disease Unit, Department of Internal Medicine, University of Pisa, Pisa, Italy
    Antivir Ther 15:35-44. 2010
    ..In this article, we review current opinions on the appropriate use of diagnostic procedures, answering some important questions for the clinician, such as why, how, when and in whom they might best be used...
  6. pmc Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B
    F Bonino
    University of Pisa and Foundation IRCCS, Policlinico di Milano, Milan, Italy
    Gut 56:699-705. 2007
    ..The effect of pre-treatment factors on post-treatment responses was investigated...
  7. ncbi request reprint Chronic hepatitis B e antigen (HBeAg) negative, anti-HBe positive hepatitis B: an overview
    Ferruccio Bonino
    Direzione Scientifica, Ospedale Maggiore di Milano, Policlinico, IRCCS, Via Francesco Sforza, 28, 20122 Milan, Italy
    J Hepatol 39:S160-3. 2003
  8. doi request reprint Early and accurate prediction of Peg-IFNs/ribavirin therapy outcome in the individual patient with chronic hepatitis C by modeling the dynamics of the infected cells
    P Colombatto
    UO Epatologia SSN, Azienda Ospedaliero Universitaria Pisana, Pisa, Italy
    Clin Pharmacol Ther 84:212-5. 2008
    ..Overall, the duration of therapy would have been 49 months less than that suggested by the most recent algorithms based on a rapid virological response (RVR) at week 4...
  9. ncbi request reprint Emergence of hepatitis B virus quasispecies with lower susceptibility to nucleos(t)ide analogues during lamivudine treatment
    F Moriconi
    UO Gastroenterologia ed Epatologia Ospedaliera, University Hospital of Pisa, Pisa, Italy
    J Antimicrob Chemother 60:341-9. 2007
    ..We studied the impact of hepatitis B virus (HBV) polymerase/reverse transcriptase (Pol/Rt) heterogeneity on adefovir rescue therapy in 34 consecutive chronic hepatitis B patients with viral breakthrough during lamivudine monotherapy...
  10. ncbi request reprint Impact of antiviral treatment on recurrence of hepatitis B virus infection and disease
    P Ciccorossi
    U O Gastroenterologia e Epatologia, Azienda Ospedaliera Pisana e Università di Pisa, Pisa, Italy
    Transplant Proc 35:1028-9. 2003
  11. ncbi request reprint Transient elastography: a new surrogate marker of liver fibrosis influenced by major changes of transaminases
    B Coco
    UO Gastroenterologia ed Epatologia Ospedaliera, Azienda Ospedaliero Universitaria Pisana, Pisa, Italy
    J Viral Hepat 14:360-9. 2007
    ....
  12. ncbi request reprint A multiphase model of the dynamics of HBV infection in HBeAg-negative patients during pegylated interferon-alpha2a, lamivudine and combination therapy
    Piero Colombatto
    UO Gastroenterologia ed Epatologia Ospedaliera, Azienda Ospedaliero Universitaria Pisana, Pisa, Italy
    Antivir Ther 11:197-212. 2006
    ..3 log10, P = 0.039). In conclusion, peg-IFN-alpha2a, in spite of having direct antiviral activity lower than that of 3TC, achieved a comparable reduction of infected hepatocytes, possibly because of a higher infected cell clearance rate...
  13. doi request reprint Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B
    Maurizia Rossana Brunetto
    UO Epatologia, Azienda Ospedaliero Universitaria Pisana, Pisa, Italy
    Hepatology 49:1141-50. 2009
    ..An HBsAg level <10 IU/mL at week 48 and on-treatment decline >1 log(10) IU/mL were significantly associated with sustained HBsAg clearance 3 years after treatment (both P < 0.0001)...
  14. ncbi request reprint Increasing serum levels of IgM anti-HCV are diagnostic of recurrent hepatitis C in liver transplant patients with ALT flares
    P Ciccorossi
    U O Gastroenterologia e Epatologia, Azienda Ospedaliera Pisana e Università di Pisa, Via Paradisa 2, Ospedale Cisanello, 56124 Pisa, Italy
    J Viral Hepat 10:168-73. 2003
    ..9% diagnostic accuracy...
  15. pmc Multicenter evaluation of the Elecsys hepatitis B surface antigen quantitative assay
    B J Zacher
    Medizinische Hochschule Hannover, Klinik fur Gastroenterologie, Hepatologie und Endokrinologie, Carl Neuberg Str 1, 30625 Hannover, Germany
    Clin Vaccine Immunol 18:1943-50. 2011
    ..4 to 9.6; HBsAg concentrations, 0.1 to 37,300 IU/ml). The Elecsys HBsAg II quantitative assay accurately and reliably quantifies HBsAg in routine clinical samples. Onboard dilution minimizes retesting and reduces the potential for error...
  16. ncbi request reprint Validation and comparison of different PCR-based methods for detection of hepatitis B virus precore region mutants
    D Flichman
    UO Gastroenterologia ed Epatologia, Azienda Ospedaliero Universitaria Pisana, Via Paradisa 2, 56124 Pisa, Italy
    J Virol Methods 129:64-74. 2005
    ..In conclusion, an accurate characterization of HBV precore heterogeneity should be warranted by a careful choice of the most appropriate assay according to the aim of the study...
  17. ncbi request reprint Personalized therapy in chronic viral hepatitis
    Maurizia Rossana Brunetto
    Gastroenterology and Hepatology Unit, University Hospital of Pisa, Via Paradisa 2, 56124 Cisanello, Pisa, Italy
    Mol Aspects Med 29:103-11. 2008
    ..We provide a concise review of the potentials of this approach in clinical practice...
  18. ncbi request reprint Treatment of HBeAg-negative chronic hepatitis B with interferon or pegylated interferon
    Maurizia Rossana Brunetto
    U O Gastroenterologia ed Epatologia, Azienda Ospedaliera, Universitaria Pisana, Pisa, Italy
    J Hepatol 39:S164-7. 2003
  19. ncbi request reprint Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers
    Maurizia Rossana Brunetto
    Hepatology Unit, University Hospital of Pisa, University of Pisa, Pisa, Italy
    Gastroenterology 139:483-90. 2010
    ..We studied whether hepatitis B surface antigen (HBsAg) serum levels (HBsAgsl) quantification may contribute to diagnosis of HBV phases in untreated hepatitis B e antigen-negative genotype D asymptomatic carriers...
  20. ncbi request reprint Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study
    Maurizia Rossana Brunetto
    U O Gastroenterologia ed Epatologia, Spedali Riuniti di Santa Chiara, Via Paradisa n 2 Cisanello, 56124 Pisa, Italy
    J Hepatol 36:263-70. 2002
    ....
  21. pmc Bio-mathematical models of viral dynamics to tailor antiviral therapy in chronic viral hepatitis
    Maurizia Rossana Brunetto
    UO Epatologia, Azienda Ospedaliero Universitaria Pisana, 56100 Pisa, Italy
    World J Gastroenterol 15:531-7. 2009
    ....
  22. ncbi request reprint Treatment of chronic hepatitis B: from research to clinical practice via the consensus conferences
    M R Brunetto
    U O Gastroenterologia e Epatologia, Azienda Ospedaliera Pisana, Via Paradisa 2, 56124 Cisanello, Pisa, Italy
    Curr Pharm Des 10:2063-75. 2004
    ..In perspectives, currently available molecular and immunologic tools and modelling of viral dynamics will help to address the therapy issue with more complex, efficacious and individually tailored treatment schedules...
  23. ncbi request reprint Subthreshold mania as predictor of depression during interferon treatment in HCV+ patients without current or lifetime psychiatric disorders
    Stefano Pini
    Department of Psychiatry, University of Pisa, Pisa, Italy
    J Psychosom Res 62:349-55. 2007
    ..We analyzed the impact of lifetime manic-hypomanic symptoms and anxiety on the development of depression in hepatitis-C-virus-infected subjects treated with two different types of IFN-alpha...
  24. ncbi request reprint Sustained response to interferon-ribavirin combination therapy predicted by a model of hepatitis C virus dynamics using both HCV RNA and alanine aminotransferase
    Piero Colombatto
    UO Gastroenterologia ed Epatologia, Azienda Ospedaliero Universitaria Pisana, Pisa, Italy
    Antivir Ther 8:519-30. 2003
    ..However, they are unable to predict whether the response will be maintained. The aim of our work was to identify criteria by which sustained responses may be predicted and defined...
  25. ncbi request reprint Animal model for liver cell banking from non-heart beating donors after prolonged ischaemia time
    L Porretti
    Center of Transfusion Medicine, Cell Therapy and Cryobiology, IRCCS Fondazione Ospedale Policlinico, Mangiagalli e Regina Elena, Via Francesco Sforza 35, 20122 Milan, Italy
    Dig Liver Dis 38:905-11. 2006
    ..Thus, we investigated if prolonged ischaemia could influence the recovery and viability of functional hepatocytes dissociated from rat livers...
  26. ncbi request reprint Viral load 1 week after liver transplantation, donor age and rejections correlate with the outcome of recurrent hepatitis C
    Pietro Ciccorossi
    U O Gastroenterologia e Epatologia, Pisa, Italy
    Liver Int 27:612-9. 2007
    ..Early identification of patients at a higher risk of rapidly progressive recurrent hepatitis post liver transplantation (LT) could help to tailor antiviral therapy...
  27. ncbi request reprint Software and expert system for the management of chronic hepatitis B
    Riccardo Neirotti
    Direzione Scientifica, Fondazione IRCCS, Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena, Milano, Italy
    J Clin Virol 34:S29-33. 2005
    ..The ICT infrastructure designed for this purpose includes four sets of online accessible software tools:..
  28. ncbi request reprint Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis
    Vincenzo Mazzaferro
    Department of Surgery, Biomedical Statistics, Pathology, National Cancer Institute of Milan and Chair of Gastroenterology, Policlinico Foundation, Department of Medicine, University of Milan, Italy
    Hepatology 44:1543-54. 2006
    ..3; 95% CI: 0.09-0.9; P = .04). In conclusion, IFN does not affect overall prevention of HCC recurrence after resection, but it may reduce late recurrence in HCV-pure patients receiving effective treatment...
  29. ncbi request reprint Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B
    Patrick Marcellin
    Service d Hepatologie, INSERM Unité 481 and Centre de Recherches Claude Bernard sur les Hépatites Virales, Hopital Beaujon, Clichy, France
    N Engl J Med 351:1206-17. 2004
    ..As a result, nucleoside and nucleotide analogues are typically continued indefinitely, a strategy associated with the risk of resistance and unknown long-term safety implications...
  30. ncbi request reprint Severe liver disease is caused by HBV rather than HCV in children with hematological malignancies
    Manal H El-Sayed
    Pediatric Department, Hematology Oncology Division, Children s Hospital, Ain Shams University, Abassyia, Cairo, Egypt
    Hematol J 4:321-7. 2003
    ..001, respectively). In all, 70% of HBV-infected children suffered chemotherapy-associated flares. None of the thalassemics had severe hepatitis exacerbations; 94% had HCV markers with none HBV-DNA(+). One died of progressive cirrhosis...
  31. ncbi request reprint Comparable functions of plasmacytoid and monocyte-derived dendritic cells in chronic hepatitis C patients and healthy donors
    Diego Piccioli
    Immunology and Virology Department, Chiron Vaccines Research Center, Via Fiorentina 1, 53100 Siena, Italy
    J Hepatol 42:61-7. 2005
    ..To investigate whether DC dysfunction is involved in this process, we have studied monoycte-derived DCs (Mo-DCs) and plasmacytoid DCs (pDCs), which produce large amounts of IFN-alpha, from chronic HCV patients and healthy donors...